Cardlytics R&D Spending Growth & History (CDLX)
Cardlytics's r&d spending was $39.8M for fiscal 2025.
View full Cardlytics company overviewCardlytics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $39.8M | −$9.8M | −19.84% |
| 2024 | 2024-12-31 | $49.6M | −$1.7M | −3.40% |
| 2023 | 2023-12-31 | $51.4M | −$3.1M | −5.66% |
| 2022 | 2022-12-31 | $54.4M | $16.3M | +42.86% |
| 2021 | 2021-12-31 | $38.1M | $20.6M | +117.34% |
| 2020 | 2020-12-31 | $17.5M | $5.8M | +49.86% |
| 2019 | 2019-12-31 | $11.7M | −$4.5M | −27.83% |
| 2018 | 2018-12-31 | $16.2M | $4.1M | +33.42% |
| 2017 | 2017-12-31 | $12.2M | −$1.8M | −12.60% |
| 2016 | 2016-12-31 | $13.9M | — | — |
Cardlytics quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.5M | −$4.3M | −43.85% |
| Q1 2026 | 2026-03-31 | $6.4M | −$3.8M | −37.44% |
| Q4 2025 | 2025-12-31 | $10.8M | $926,000 | +9.36% |
| Q3 2025 | 2025-09-30 | $8.8M | −$4.4M | −33.31% |
| Q2 2025 | 2025-06-30 | $9.9M | −$3.6M | −26.75% |
| Q1 2025 | 2025-03-31 | $10.3M | −$2.8M | −21.23% |
| Q4 2024 | 2024-12-31 | $9.9M | −$2.6M | −20.91% |
| Q3 2024 | 2024-09-30 | $13.2M | $764,000 | +6.15% |
| Q2 2024 | 2024-06-30 | $13.5M | −$1.4M | −9.27% |
| Q1 2024 | 2024-03-31 | $13.0M | $1.5M | +12.83% |
| Q4 2023 | 2023-12-31 | $12.5M | −$2.3M | −15.47% |
| Q3 2023 | 2023-09-30 | $12.4M | −$1.3M | −9.68% |
| Q2 2023 | 2023-06-30 | $14.8M | $1.3M | +9.32% |
| Q1 2023 | 2023-03-31 | $11.6M | −$727,000 | −5.91% |
| Q4 2022 | 2022-12-31 | $14.8M | $3.0M | +25.32% |
| Q3 2022 | 2022-09-30 | $13.8M | $2.6M | +23.53% |
| Q2 2022 | 2022-06-30 | $13.6M | $4.6M | +52.01% |
| Q1 2022 | 2022-03-31 | $12.3M | $6.1M | +97.67% |
| Q4 2021 | 2021-12-31 | $11.8M | $6.7M | +132.13% |
| Q3 2021 | 2021-09-30 | $11.1M | $6.5M | +140.78% |
| Q2 2021 | 2021-06-30 | $8.9M | $5.0M | +125.26% |
| Q1 2021 | 2021-03-31 | $6.2M | $2.4M | +61.46% |
| Q4 2020 | 2020-12-31 | $5.1M | $2.1M | +72.01% |
| Q3 2020 | 2020-09-30 | $4.6M | $1.6M | +53.31% |
| Q2 2020 | 2020-06-30 | $4.0M | $1.2M | +42.56% |
| Q1 2020 | 2020-03-31 | $3.9M | $910,000 | +30.94% |
| Q4 2019 | 2019-12-31 | $3.0M | −$808,000 | −21.46% |
| Q3 2019 | 2019-09-30 | $3.0M | −$1.1M | −26.34% |
| Q2 2019 | 2019-06-30 | $2.8M | −$2.1M | −43.09% |
| Q1 2019 | 2019-03-31 | $2.9M | −$518,000 | −14.98% |
| Q4 2018 | 2018-12-31 | $3.8M | $1.1M | +43.58% |
| Q3 2018 | 2018-09-30 | $4.1M | $676,000 | +19.76% |
| Q2 2018 | 2018-06-30 | $4.9M | $1.8M | +58.03% |
| Q1 2018 | 2018-03-31 | $3.5M | $446,000 | +14.80% |
| Q4 2017 | 2017-12-31 | $2.6M | — | — |
| Q3 2017 | 2017-09-30 | $3.4M | — | — |
| Q2 2017 | 2017-06-30 | $3.1M | — | — |
| Q1 2017 | 2017-03-31 | $3.0M | — | — |
Cardlytics r&d spending trends
Over the last five fiscal years, Cardlytics's r&d spending increased from $17.5M to $39.8M, a change of $22.2M. The latest reported quarter, Q2 2026, shows $5.5M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardlytics source filings ↗